Kahan, ZsuzsannaGil-Gil, MiguelRuiz-Borrego, ManuelCarrasco, EvaCiruelos, EvaMuñoz, MontserratBermejo, BegoñaMargeli, MireiaAnton, AntonioCasas, MaribelCsoszi, TiborMurillo, LauraMorales, SerafinCalvo, LourdesLang, IstvanAlba, Emiliode-la-Haba-Rodriguez, JuanRamos, ManuelAlvarez-Lopez, IsabelGal-Yam, EinavGarcia-Palomo, AndresAlvarez, ElenaGonzalez-Santiago, SantiagoRodriguez, Cesar AServitja, SoniaCorsaro, MassimoRodrigalvarez, GracielaZielinski, ChristophMartin, Miguel2023-02-092023-02-092021-07-07Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Eur J Cancer. 2021 Oct;156:70-82http://hdl.handle.net/10668/18401The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was better tolerated. This analysis compared patient-reported outcomes. The PEARL quality of life (QoL) population comprised 537 patients, 268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression models, respectively. Questionnaire completion rate was high and similar between treatment arms. Significant differences were observed in the mean change in global health status (GHS)/QoL scores from the baseline to cycle 3 (2.9 for palbociclib/ET vs. -2.1 for capecitabine (95% confidence interval [CI], 1.4-8.6; P = 0.007). The median TTD in GHS/QoL was 8.3 months for palbociclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Similar improvements for palbociclib/ET were also seen for other scales as physical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differences were observed between the treatment arms in change from the baseline in any item of the EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale. Patients receiving palbociclib/ET experienced a significant delay in deterioration of GHS/QoL and several functional and symptom scales compared with capecitabine, providing additional evidence that palbociclib/ET is better tolerated.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/CDK4/6 inhibitorEndocrine therapyHealth-related quality of lifeHormone receptor–positive metastatic breast cancerPalbociclibAndrostadienesAntimetabolites, antineoplasticAntineoplastic agents, hormonalAntineoplastic combined chemotherapy protocolsAromatase inhibitorsBreast neoplasmsCapecitabineDisease progressionEstrogen receptor antagonistsEuropeFemaleFulvestrantHealth statusHumansIsraelNeoplasm metastasisPatient reported outcome measuresPiperazinesPostmenopauseProgression-free survivalProtein kinase inhibitorsPyridinesQuality of lifeTime factorsresearch article34425406open accessAndrostadienosAntagonistas del receptor de estrógenoAntimetabolitos antineoplásicosAntineoplásicos hormonalesCapecitabinaInhibidores de la aromatasaNeoplasias de la mamaProgresión de la enfermedadProtocolos de quimioterapia combinada antineoplásica10.1016/j.ejca.2021.07.0041879-0852http://www.ejcancer.com/article/S0959804921004408/pdf